How to Measure Unbound Drug Target in a Sample

This patent describes a laboratory method for accurately measuring the amount of a specific target molecule (antigen) that is not yet bound by a complex drug (multispecific antibody) in a sample, which is important for drug development.

What it covers

This method helps scientists determine the amount of 'free antigen' in a sample that also contains a 'multispecific antibody' drug. First, the sample is mixed with a 'second antigen' that specifically attaches to a different part of the multispecific antibody, forming a 'second antigen-multispecific antibody complex' (Claim 11). This complex is then removed from the sample (Claim 11), leaving behind a 'multispecific antibody-depleted sample'. Finally, the amount of the original free antigen in this depleted sample is measured (Claim 14). For example, if a drug binds to both a cancer cell marker and a blood protein, this method allows researchers to precisely measure how much of the cancer cell marker is still available, not yet bound by the drug.

What it doesn't cover

• —Does not cover methods for detecting free antigen of a monospecific antibody (an antibody that only binds to one type of target).
• —Does not cover methods that measure the total amount of antigen, only the *free* or unbound antigen.
• —Does not cover methods that do not involve removing the multispecific antibody from the sample before measuring the free antigen.
• —Does not cover methods where the multispecific antibody is depleted using an anti-idiotypic antibody instead of a 'second antigen'.
• —Does not cover methods where the second antigen binds to the *same* binding specificity as the first antigen.

The clever bit

The clever part is specifically removing the multispecific antibody from the sample *before* measuring the free antigen. This is done by using a 'second antigen' that binds to a *different* part of the drug, ensuring that only the truly unbound target molecule is measured, preventing the drug from interfering with the measurement.

Why it matters

Accurately measuring free antigen is critical in the development and testing of new antibody drugs. It helps researchers understand how much of a drug is actually available to bind to its intended target in the body, which directly impacts drug dosing, effectiveness, and safety. This method provides a way to get a clearer picture of drug-target engagement without interference from the drug itself.

Real-world examples

• 1.Development of bispecific antibodies for cancer immunotherapy
• 2.Measuring drug-target engagement for multispecific antibodies in clinical trials
• 3.Pharmacokinetic studies for complex biologic drugs
• 4.Research into autoimmune disease treatments using multispecific antibodies